BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 27733013)

  • 1. DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia.
    Patnaik MM; Barraco D; Lasho TL; Finke CM; Hanson CA; Ketterling RP; Gangat N; Tefferi A
    Am J Hematol; 2017 Jan; 92(1):56-61. PubMed ID: 27733013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic score including gene mutations in chronic myelomonocytic leukemia.
    Itzykson R; Kosmider O; Renneville A; Gelsi-Boyer V; Meggendorfer M; Morabito M; Berthon C; Adès L; Fenaux P; Beyne-Rauzy O; Vey N; Braun T; Haferlach T; Dreyfus F; Cross NC; Preudhomme C; Bernard OA; Fontenay M; Vainchenker W; Schnittger S; Birnbaum D; Droin N; Solary E
    J Clin Oncol; 2013 Jul; 31(19):2428-36. PubMed ID: 23690417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia.
    Patnaik MM; Lasho TL; Vijayvargiya P; Finke CM; Hanson CA; Ketterling RP; Gangat N; Tefferi A
    Blood Cancer J; 2016 Jan; 6(1):e385. PubMed ID: 26771811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia.
    Kim HY; Lee KO; Park S; Jang JH; Jung CW; Kim SH; Kim HJ
    Ann Lab Med; 2018 Nov; 38(6):495-502. PubMed ID: 30027691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia.
    Kar SA; Jankowska A; Makishima H; Visconte V; Jerez A; Sugimoto Y; Muramatsu H; Traina F; Afable M; Guinta K; Tiu RV; Przychodzen B; Sakaguchi H; Kojima S; Sekeres MA; List AF; McDevitt MA; Maciejewski JP
    Haematologica; 2013 Jan; 98(1):107-13. PubMed ID: 22773603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features.
    Palomo L; Garcia O; Arnan M; Xicoy B; Fuster F; Cabezón M; Coll R; Ademà V; Grau J; Jiménez MJ; Pomares H; Marcé S; Mallo M; Millá F; Alonso E; Sureda A; Gallardo D; Feliu E; Ribera JM; Solé F; Zamora L
    Oncotarget; 2016 Aug; 7(35):57021-57035. PubMed ID: 27486981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia.
    Sehgal AR; Gimotty PA; Zhao J; Hsu JM; Daber R; Morrissette JD; Luger S; Loren AW; Carroll M
    Clin Cancer Res; 2015 Apr; 21(7):1614-20. PubMed ID: 25609058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular features of 109 patients with chronic myelomonocytic leukemia in a single center].
    Qu SQ; Pan LJ; Qin TJ; Xu ZF; Li B; Wang HJ; Sun Q; Jia YJ; Li CW; Cai WY; Gao QY; Jiao M; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):373-379. PubMed ID: 37550186
    [No Abstract]   [Full Text] [Related]  

  • 9. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes.
    Patnaik MM; Padron E; LaBorde RR; Lasho TL; Finke CM; Hanson CA; Hodnefield JM; Knudson RA; Ketterling RP; Al-kali A; Pardanani A; Ali NA; Komrokji RS; Tefferi A
    Leukemia; 2013 Jul; 27(7):1504-10. PubMed ID: 23531518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study.
    Wassie EA; Itzykson R; Lasho TL; Kosmider O; Finke CM; Hanson CA; Ketterling RP; Solary E; Tefferi A; Patnaik MM
    Am J Hematol; 2014 Dec; 89(12):1111-5. PubMed ID: 25195656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.
    Patnaik MM; Wassie EA; Padron E; Onida F; Itzykson R; Lasho TL; Kosmider O; Finke CM; Hanson CA; Ketterling RP; Komrokji R; Tefferi A; Solary E
    Blood Cancer J; 2015 Jan; 5(1):e270. PubMed ID: 25555161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance.
    Patnaik MM; Lasho TL; Finke CM; Hanson CA; Hodnefield JM; Knudson RA; Ketterling RP; Pardanani A; Tefferi A
    Am J Hematol; 2013 Mar; 88(3):201-6. PubMed ID: 23335386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.
    Patnaik MM; Itzykson R; Lasho TL; Kosmider O; Finke CM; Hanson CA; Knudson RA; Ketterling RP; Tefferi A; Solary E
    Leukemia; 2014 Nov; 28(11):2206-12. PubMed ID: 24695057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted sequencing aids in identifying clonality in chronic myelomonocytic leukemia.
    Hwang SM; Kim SM; Nam Y; Kim J; Kim S; Ahn YO; Park Y; Yoon SS; Shin S; Kwon S; Lee DS
    Leuk Res; 2019 Sep; 84():106190. PubMed ID: 31377458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management.
    Patnaik MM; Tefferi A
    Am J Hematol; 2016 Jun; 91(6):631-42. PubMed ID: 27185207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.
    Ouyang Y; Qiao C; Chen Y; Zhang SJ
    Oncotarget; 2017 Mar; 8(13):20834-20841. PubMed ID: 28209919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome.
    Patnaik MM; Wassie EA; Lasho TL; Hanson CA; Ketterling R; Tefferi A
    Am J Hematol; 2015 May; 90(5):411-6. PubMed ID: 25645147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis.
    Lin Y; Zheng Y; Wang ZC; Wang SY
    Hematology; 2016 Sep; 21(8):454-61. PubMed ID: 27077763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia.
    Elliott MA; Pardanani A; Hanson CA; Lasho TL; Finke CM; Belachew AA; Tefferi A
    Am J Hematol; 2015 Jul; 90(7):653-6. PubMed ID: 25850813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.
    Khan M; Muzzafar T; Kantarjian H; Badar I; Short N; Wang X; Chamoun K; Jain P; DiNardo C; Pemmaraju N; Bose P; Borthakur G; Cortes J; Verstovsek S; Garcia-Manero G; Estrov Z
    Ann Hematol; 2018 Jul; 97(7):1183-1191. PubMed ID: 29557496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.